Cohort study of Patients with metastatic colorectal cancer Treated by XELOX with bevacizumab
Not Applicable
Completed
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000004896
- Lead Sponsor
- agoya City University Gastrointestinal Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1. Prior or synchronous invasive malignancy unless disease free for a minimum of 5 years 2.Previous history of severe drug-induced allergy caused by capecitabine 3.Be Administered or less than 7 days finished administration Compound Drug of tegafur,gimeracil and oteracil potassium 4.Severe kidney trouble 5.Previous history of severe drug-induced allergy caused by oxaliplatin 6. Neuropathy or sensory dysfunction 7.Previous history of severe drug-induced allergy caused by bevacizumab 8.Pregnant women who are capable of pregnancy or intend to get pregnant 9.Patients judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency and Degree of Hand-foot symdrome(HFS),Neuropathy and Vascular disorders
- Secondary Outcome Measures
Name Time Method Time To Failure, Disease Free Survival, Overall Survival, Overall Response Rate, Frequency and Degree of Adverse Events Except HFS,Neuropathy and Vascular disorders. Resection Rate of Liver Metastases, Rate of R0 Resection of Liver Metastases